Wells Fargo & Company Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Wells Fargo & Company raised its price target for Kiniksa Pharmaceuticals International stock from $42.00 to $45.00, indicating a potential upside of 24.22% from the current price.
• The stock has received multiple positive ratings, including upgrades to "strong-buy" and "buy" from several research firms, with a consensus rating of "Buy" and an average price target of $41.67.
• Kiniksa Pharmaceuticals reported a net revenue of $156.80 million in its last quarterly earnings, exceeding analysts' expectations by $11.59 million.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its price target increased by research analysts at Wells Fargo & Company from $42.00 to $45.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential upside of 24.22% from the stock's current price.

A number of other research firms also recently weighed in on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Finally, Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $41.67.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded up $0.14 during midday trading on Thursday, reaching $36.23. The company had a trading volume of 40,254 shares, compared to its average volume of 649,624. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $37.34. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of 907.35 and a beta of 0.20. The company has a fifty day simple moving average of $33.09 and a two-hundred day simple moving average of $27.91.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 17,000 shares of the stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the completion of the transaction, the chief accounting officer directly owned 33,041 shares in the company, valued at approximately $1,068,876.35. This represents a 33.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares of the company's stock, valued at approximately $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 561,371 shares of company stock valued at $18,825,009 in the last ninety days. Corporate insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KNSA. Bank of America Corp DE grew its stake in Kiniksa Pharmaceuticals International by 2.2% in the fourth quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock valued at $4,268,000 after purchasing an additional 4,654 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Kiniksa Pharmaceuticals International by 6.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock valued at $432,000 after buying an additional 1,380 shares during the last quarter. ProShare Advisors LLC lifted its stake in Kiniksa Pharmaceuticals International by 35.5% during the 4th quarter. ProShare Advisors LLC now owns 12,807 shares of the company's stock valued at $253,000 after acquiring an additional 3,357 shares during the period. Squarepoint Ops LLC purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at $530,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Kiniksa Pharmaceuticals International by 28.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock worth $1,121,000 after purchasing an additional 12,462 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.